The Food and Drug Administration (FDA) has approved a higher recommended dose of the immunotherapy Keytruda (pembrolizumab), taken less often, for adult patients across all cancer types in which the drug is used.
FDA Approves Every Six-Week Dose of Keytruda Across All Indicated Cancer Types